Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients.

Authors :: Boons, Christel C. L. M.
Tromp, Vashti N. M. F.
Neppelenbroek, Nienke J. M.
Timmers, Lonneke
van Schoor, Natasja M.
Swart, Eleonora L.
Hendrikse, N. Harry
Janssen, Jeroen J. W. M.
Hugtenburg, Jacqueline G.
Source :: Acta Oncologica; Jun2019, Vol. 58 Issue 6, p891-896, 6p, 4 Charts
Publication Year :: 2019
Abstract: The article offers information on the Chronic myeloid leukemia (CML), a chronic myeloproliferative disease, consistently associated with the presence of the Philadelphia chromosome coding for the BCR-ABL oncoprotein. It mentions the use of tyrosine kinase inhibitors (TKIs) in CML has highly improved prognosis of CML patients; and also mentions adequate provision of information is an important determinant of both medication adherence in CML and successful management of side effects.

Subjects :: CHI-squared test
COMMUNICATION
CONFIDENCE intervals
DRUGS
DRUG side effects
PATIENT compliance
PATIENT education
PATIENT satisfaction
QUESTIONNAIRES
STATISTICAL hypothesis testing
LOGISTIC regression analysis
SECONDARY analysis
CHRONIC myeloid leukemia
DATA analysis software
DESCRIPTIVE statistics
NILOTINIB
THERAPEUTICS

Full Text Access

Tools